Alexia Nedel Sant’Ana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alexia Nedel Sant’Ana has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Aparecida Paz
Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil
1 shared publication - Ana Paula Alegretti
Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil
1 shared publication - Camila Kehl Dias
Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-003, Brazil
1 shared publication - Claudia Caceres Astigarraga
Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil
1 shared publication - Fabrício Figueiró
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil
1 shared publication - Humberto Cardoso Alves
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-003, Brazil
1 shared publication
Latest Publications
- Open Access
LSC-like Phenotypes Aid in the Prognosis of Adult and Elderly Acute Myeloid Leukemia Patients at a Resource-Limited Health Center
Background/Objectives: Relapse is the greatest obstacle in treating acute myeloid leukemia (AML), occurring in 40–50% of younger patients and most elderly patients. Current immunophenotyping panels for diagnosis and detection of measurable residual disease (MRD) primarily focus on detecting blasts, thereby overlooking AML heterogeneity, which could provide valuable prognostic insights. In this context, we propose repositioning EuroFlow panels within a new set of analyses to assess leukemia stem-like phenotypes for AML prognostic monitoring. Methods: We performed a retrospective study with AML patients at the Hospital de Clínicas de Porto Alegre between 2015 and 2023. Results: Our findings highlight the relevance of leukemia stem cell-like phenotypes, particularly the CD123+, CD34+CD123+, and CD34+CD38− subpopulations, for complementary prognostication of adult and elderly patients. A higher percentage of CD123+ cells was a risk factor for both RFS (p = 0.04) and OS (p = 0.02), whereas an increase in CD34+CD123+ cells was a risk factor for RFS (p = 0.04) only. A higher percentage of CD34+CD38− cells was a risk factor for OS (p = 0.002). From diagnosis to the second monitoring, the CD34+ subpopulation was a more relevant prognostic factor in elderly individuals than in adults. CD34&CD38 most immature subpopulations may increase with poor-prognosis markers in both adults and the elderly. Conclusions: Repositioning immunophenotypic analyses may offer a cost-effective alternative for refined prognostication, particularly in healthcare centers that already have flow cytometry-based AML diagnostics.
Open AccessLSC-like Phenotypes Aid in the Prognosis of Adult and Elderly Acute Myeloid Leukemia Patients at a Resource-Limited Health Center
Background/Objectives: Relapse is the greatest obstacle in treating acute myeloid leukemia (AML), occurring in 40–50% of younger patients and most elderly patients. Current immunophenotyping panels for diagnosis and detection of measurable residual disease (MRD) primarily focus on detecting blasts, thereby overlooking AML heterogeneity, which could provide valuable prognostic insights. In this context, we propose repositioning EuroFlow panels within a new set of analyses to assess leukemia stem-like phenotypes for AML prognostic monitoring. Methods: We performed a retrospective study with AML patients at the Hospital de Clínicas de Porto Alegre between 2015 and 2023. Results: Our findings highlight the relevance of leukemia stem cell-like phenotypes, particularly the CD123+, CD34+CD123+, and CD34+CD38− subpopulations, for complementary prognostication of adult and elderly patients. A higher percentage of CD123+ cells was a risk factor for both RFS (p = 0.04) and OS (p = 0.02), whereas an increase in CD34+CD123+ cells was a risk factor for RFS (p = 0.04) only. A higher percentage of CD34+CD38− cells was a risk factor for OS (p = 0.002). From diagnosis to the second monitoring, the CD34+ subpopulation was a more relevant prognostic factor in elderly individuals than in adults. CD34&CD38 most immature subpopulations may increase with poor-prognosis markers in both adults and the elderly. Conclusions: Repositioning immunophenotypic analyses may offer a cost-effective alternative for refined prognostication, particularly in healthcare centers that already have flow cytometry-based AML diagnostics.